No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics: 2024 Financial and Strategic Highlights
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
JMP Securities Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4
Strategic Advancements and Financial Health Propel Context Therapeutics to a 'Buy' Rating
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth